PICC Line Occlusions: Understanding the How and Why for Prevention
According to iData Research (iData Research, Vascular Access Devices Market Analysis, 2020-2026 MedSuite, Vancouver, BC), more than 340 million peripheral (PIV) and 7 million central venous catheters (CVC) are purchased for use each year in the USA.1 More than 30% of patients with vascular access devices (VAD) will experience complications.
Introducing MIMIX Technology
A new novel biomaterial has been created to mimic the body’s natural chemistry and thus avoid the foreign body response. MIMIX is a new consistently hydrophilic biomaterial from Access Vascular that has the potential to change how not only vascular access devices are made - but many other healthcare technologies.
CLABSI: An Ounce of Prevention
The rise of dangerous Central Line Associated Blood Stream Infections (CLABSI) should spur a review of your hospital’s vascular access program. Here are some basic strategies to diminish the risk.
The Implication of Complications
Complications from vascular access devices can prove deadly to patients and detrimental to hospital economics with reimbursement penalties tied to these complications. The good news is they can be greatly reduced with targeted tracking and common-sense measures.